Article
Agronomy
Zhenxin Wang, Chunyan Zhan, Yingying Zhang, Lin Zhang, Jiaolong Li, Tong Xing, Liang Zhao, Jianfei Wang, Feng Gao
Summary: This study investigated the effects of dietary corn-resistant starch on bile acid metabolism in broilers. The results showed that resistant starch supplementation reduced lipid levels and altered bile acid synthesis and reabsorption capacities in broilers.
Review
Biochemistry & Molecular Biology
Jing Zeng, Jiangao Fan, Huiping Zhou
Summary: Chronic cholestatic liver diseases, such as primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC), gradually progress to liver fibrosis, cirrhosis, and failure. Disruption of bile acid metabolism and intrahepatic circulation plays a crucial role in accelerating the progression of cholestatic liver diseases. Bile acids not only act as detergents for nutrition absorption but also function as key signaling molecules that regulate hepatic metabolism and immune responses. This review focuses on the role of bile acid-mediated signaling in cholestatic liver disease.
CELL AND BIOSCIENCE
(2023)
Article
Oncology
Michala G. Rolver, Lya K. K. Holland, Muthulakshmi Ponniah, Nanditha S. Prasad, Jiayi Yao, Julie Schnipper, Signe Kramer, Line Elingaard-Larsen, Elena Pedraz-Cuesta, Bin Liu, Luis A. Pardo, Kenji Maeda, Albin Sandelin, Stine Falsig Pedersen
Summary: The mechanisms connecting acidic tumor microenvironments to disease progression are not yet fully understood. This study reveals that cancer cells adapted to an acidic pH environment exhibit increased capacity for acid extrusion and higher intracellular pH at physiological pH levels. This adaptation is associated with metabolic changes favoring oxidative metabolism, increased lipid content, peroxisome proliferation, and mitochondrial fusion. The upregulation of PPAR alpha, stimulated by increased fatty acid uptake, drives the metabolic changes by promoting mitochondrial and peroxisomal energy metabolism while limiting glycolysis. Inhibition of PPAR alpha results in increased sensitivity of acid-adapted cancer cells.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Article
Multidisciplinary Sciences
Jiaqi Fu, Yuqin Liang, Yunhe Shi, Donghua Yu, Yu Wang, Pingping Chen, Shumin Liu, Fang Lu
Summary: HQCFT may play a part in the prevention of atherosclerosis by regulating gut microbiota and bile acid metabolism, reducing plaque area, regulating lipid levels, and alleviating liver steatosis in AS mice.
Article
Nutrition & Dietetics
Ruixia Bao, Wei Wang, Beibei Chen, Jujie Pan, Qian Chen, Mengyang Liu, Dan Wang, Yuzheng Wu, Haiyang Yu, Lifeng Han, Yi Zhang, Tao Wang
Summary: This study investigates the association between uric acid and cholesterol metabolism and the effect of dioscin in preventing hyperuricemia-induced atherosclerosis. The results show that dioscin can ameliorate atherosclerosis in a hyperuricemic state and regulate the farnesoid X receptor (FXR) -small heterodimer partner (SHP) -7 alpha-hydroxylase (CYP7A1) signaling pathway in the liver. Tigogenin, a metabolite of dioscin, increases the conversion rate of cholesterols into bile acids. Clinical study also demonstrates that treatment with a dioscin-enriched preparation decreases serum cholesterol levels in individuals with hyperuricemia.
Article
Medicine, Research & Experimental
Yin Cai, Hao Liu, Erfei Song, Lin Wang, Jindong Xu, Yi He, Dengwen Zhang, Liyan Zhang, Kenneth King-yip Cheng, Leigang Jin, Min Wu, Shiming Liu, Dake Qi, Liangqing Zhang, Gary D. Lopaschuk, Sheng Wang, Aimin Xu, Zhengyuan Xia
Summary: The study revealed that Rap1(-/-) mice exhibited signs of cardiac aging associated with telomere shortening and DNA damage, influencing cardiac fatty acid metabolism and aging-related phenotypes through modulation of the p53/PPAR alpha signaling pathway.
Article
Agriculture, Multidisciplinary
Jingyue Sun, Jiemin Fan, Tingting Li, Xiaoxue Yan, Yihong Jiang
Summary: Nuciferine (NF) has a mitigating effect on non-alcoholic fatty liver disease (NAFLD) by reinforcing intestinal barrier functions, regulating lipid metabolism, improving inflammation, modulating bile acid (BA) metabolism, and regulating gut microbiota.
JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY
(2022)
Review
Endocrinology & Metabolism
Roisin Ni Dhonnabhain, Qiao Xiao, Dervla O'Malley
Summary: Functional bowel disorders like IBS are multifactorial conditions that significantly impact individuals' quality of life. Gut-brain communication, bile acid modulation, and alterations in microbial profiles could be key factors in the pathophysiology of IBS symptoms.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Article
Environmental Sciences
Yunhuan Liu, Weili Kang, Shuiping Liu, Jinyan Li, Jinyan Liu, Xingxiang Chen, Fang Gan, Kehe Huang
Summary: This study reveals a new mechanism of Cd-induced liver injury, in which Cd exposure leads to dysbiosis of gut microbiota, reduces fecal bile salt hydrolase activity, and increases the level of a certain substance in the intestine, thereby inhibiting intestinal FXR/FGF-15 signaling, increasing hepatic bile acid synthesis, and ultimately facilitating hepatic ductular proliferation, inflammation, and injury in mice.
SCIENCE OF THE TOTAL ENVIRONMENT
(2022)
Article
Biochemistry & Molecular Biology
Peng Wang, Peiqiang Yuan, Sen Lin, Heju Zhong, Xiaoling Zhang, Yong Zhuo, Jian Li, Lianqiang Che, Bin Feng, Yan Lin, Shengyu Xu, De Wu, Douglas G. Burrin, Zhengfeng Fang
Summary: This study investigated the intercorrelation between reproductive hormones and bile acids in pregnant sows and their fetuses. The newly identified PM4S and PM5S were found to be correlated with maternal and fetal bile acid homeostasis. The study confirmed the role of PM5S and PM4S as antagonists in bile acid homeostasis and FGF19 using pig hepatocytes. The pregnant sow is a promising animal model to study the pathogenesis of cholestasis during pregnancy.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Biochemistry & Molecular Biology
Masaaki Miyata, Tomoyuki Tanaka, Kazuho Takahashi, Akihiro Funaki, Yoshimasa Sugiura
Summary: Research using animal models has shown that taurine can reduce cholesterol levels, possibly by altering bile acid composition and reducing ileal FXR signaling. This study explored the mechanisms underlying the cholesterol-lowering effect of taurine in mice, revealing its potential role in modulating FXR signaling and bile acid composition to lower cholesterol levels.
Article
Gastroenterology & Hepatology
Claudia D. Fuchs, Natalie Sroda, Hubert Scharnagl, Ruchi Gupta, Wesley Minto, Tatjana Stojakovic, John T. Liles, Grant Budas, David Hollenback, Michael Trauner
Summary: This study demonstrates that cilofexor, a non-steroidal FXR agonist, improves cholestatic liver injury and hepatic fibrosis in the Mdr2-/-mouse model of sclerosing cholangitis. These findings suggest the potential therapeutic properties of cilofexor in cholestatic liver diseases, mediated by intestinal FXR-mediated gut-liver signaling.
Article
Biochemistry & Molecular Biology
Silvia Marchiano, Michele Biagioli, Rosalinda Roselli, Angela Zampella, Cristina Di Giorgio, Martina Bordoni, Rachele Bellini, Elva Morretta, Maria Chiara Monti, Eleonora Distrutti, Stefano Fiorucci
Summary: This study found that mice fed a high fat/high cholesterol diet are protected from developing a pro-atherogenic lipid profile due to their ability to dispose cholesterol through bile acids. This protective mechanism is mediated by the suppression of FXR signaling in the liver. In contrast, treatment with the FXR agonist obeticholic acid showed limited effectiveness in improving liver histopathology in patients with NAFLD, while treatment with the statin atorvastatin mitigated liver and vascular injury caused by the high fat/high cholesterol diet and increased bile acids synthesis and excretion.
Article
Pharmacology & Pharmacy
Rulin Wang, Tengteng Yuan, Jing Sun, Menghuan Yang, Yunna Chen, Lei Wang, Yanyan Wang, Weidong Chen, Daiyin Peng
Summary: Paeoniflorin alleviates estrogen-induced cholestasis by regulating bile acid transporters and synthesis enzymes, thereby maintaining bile acid homeostasis.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Microbiology
Xin Ye, Dan Huang, Zhixia Dong, Xiaoxin Wang, Min Ning, Jie Xia, Shuang Shen, Shan Wu, Yan Shi, Jingjing Wang, Xinjian Wan
Summary: Lactobacillus strains, especially Limosilactobacillus reuteri strain CGMCC 17942 and Lactiplantibacillus plantarum strain CGMCC 14407, have shown promising effects in attenuating cholesterol gallstones through the activation of the FXR signaling pathways. These strains modulate bile acid metabolism, improve gut microbiota dysbiosis, and could be a potential therapeutic strategy for treating and preventing CGS.
MICROBIOLOGY SPECTRUM
(2022)
Article
Gastroenterology & Hepatology
Mathias Jachs, Lukas Hartl, Benedikt Simbrunner, David Bauer, Rafael Paternostro, Lorenz Balcar, Benedikt Hofer, Nikolaus Pfisterer, Michael Schwarz, Bernhard Scheiner, Albert F. Staettermayer, Matthias Pinter, Michael Trauner, Mattias Mandorfer, Thomas Reiberger
Summary: In this study, it was found that carvedilol is more effective than propranolol in the secondary prophylaxis of variceal bleeding, as it induces more significant reductions in hepatic venous pressure gradient (HVPG) and is associated with lower rates of rebleeding, liver-related death, and further nonbleeding decompensation.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Michael Trauner, Christopher L. Bowlus, Aliya Gulamhusein, Bilal Hameed, Stephen H. Caldwell, Mitchell L. Shiffman, Charles Landis, Andrew J. Muir, Andrew Billin, Jun Xu, Xiangyu Liu, Xiaomin Lu, Chuhan Chung, Robert P. Myers, Kris V. Kowdley
Summary: In this 96-week open-label extension study, Cilofexor was found to be safe and effective in improving liver function and biomarkers of cholestasis and cellular injury in patients with PSC.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Jun Xu, Ya Wang, Mina Khoshdeli, Matt Peach, Jen-Chieh Chuang, Julie Lin, Wen-Wei Tsai, Sangeetha Mahadevan, Wesley Minto, Lauri Diehl, Ruchi Gupta, Michael Trauner, Keyur Patel, Mazen Noureddin, Kris Kowdley, Aliya Gulamhusein, Christopher L. Bowlus, Ryan S. Huss, Robert P. Myers, Chuhan Chung, Andrew N. Billin
Summary: This study evaluated IL-31 as a potential biomarker for pruritus in clinical trials of cilofexor, an FXR agonist, in patients with cholestatic liver diseases. IL-31 levels were found to be elevated in patients with PSC and PBC and correlated with serum bile acids. The study also showed that cilofexor therapy increased IL-31 levels in patients with NASH.
Letter
Medical Laboratory Technology
Corey Markus, Suzette Coat, Hanns-Ulrich Marschall, Susan Matthews, Tze Ping Loh, Wayne Rankin, William M. M. Hague
CLINICAL CHEMISTRY AND LABORATORY MEDICINE
(2023)
Article
Gastroenterology & Hepatology
Jasmin Zessner-Spitzenberg, Elisabeth Waldmann, Lena Jiricka, Lisa-Maria Rockenbauer, Anna Hinterberger, Jeremy Cook, Arno Asaturi, Aleksandra Szymanska, Barbara Majcher, Michael Trauner, Monika Ferlitsch
Summary: This study investigated the association of proximal serrated polyp detection rate (PSDR) and adenoma detection rate (ADR) with post-colonoscopy colorectal cancer (PCCRC) death. The results showed that both ADR and PSDR were significantly associated with PCCRC death. Therefore, striving for a high PSDR in addition to a high ADR may reduce the risk of PCCRC mortality in patients undergoing screening colonoscopy.
Article
Gastroenterology & Hepatology
Jasmin Zessner-Spitzenberg, Lena Jiricka, Elisabeth Waldmann, Lisa -Maria Rockenbauer, Jeremy Cook, Anna Hinterberger, Barbara Majcher, Aleksandra Szymanska, Arno Asaturi, Michael Trauner, Monika Ferlitsch
Summary: A retrospective study with 316,001 individuals revealed that polyps sized 10-20mm and high-grade dysplasia are significantly associated with post-colonoscopy colorectal cancer (PCCRC) mortality. Patients with polyps <10mm and without high-grade dysplasia have significantly lower PCCRC mortality compared to the general population, while those with polyps >10mm or with high-grade dysplasia do not have this advantage.
GASTROINTESTINAL ENDOSCOPY
(2023)
Article
Infectious Diseases
David Chromy, David Bauer, Benedikt Simbrunner, Mathias Jachs, Lukas Hartl, Philipp Schwabl, Teresa Binter, Lisa Steininger, Caroline Schwarz, Armin Rieger, Katharina Grabmeier-Pfistershammer, Michael Trauner, Peter Ferenci, Markus Peck-Radosavljevic, Mattias Mandorfer, Thomas Reiberger
Summary: HCV cure rates in Viennese HIV patients increased significantly from 49% in the IFN era to 88-95% in the DAA era. However, MSM-related risk behavior and reinfections have become the key challenges towards HCV elimination in HIV/HCV-coinfected patients.
INFECTIOUS DISEASES
(2023)
Article
Oncology
K. Pomej, L. Balcar, K. Shmanko, S. Welland, V. Himmelsbach, B. Scheiner, A. Mahyera, B. Mozayani, M. Trauner, F. Finkelmeier, A. Weinmann, A. Vogel, M. Pinter
Summary: There is no consensus on the optimal systemic treatment regimen for combined hepatocellular-cholangiocarcinoma (cHCC-CCA) patients. This European multicenter study analyzed the clinical characteristics and outcomes of cHCC-CCA patients, focusing on those receiving palliative systemic therapy, including immune checkpoint inhibitors (ICIs). The study found no significant difference in overall survival, progression-free survival, overall response rate, and disease control rate between patients receiving cytotoxic chemotherapy (CHT) and non-cytotoxic chemotherapy (nCHT).
Article
Gastroenterology & Hepatology
Gideon M. Hirschfield, Mitchell L. Shiffman, Aliya Gulamhusein, Kris Kowdley, John M. Vierling, Cynthia Levy, Andreas E. Kremer, Ehud Zigmond, Pietro Andreone, Stuart C. Gordon, Christopher L. Bowlus, Eric J. Lawitz, Richard J. Aspinall, Daniel S. Pratt, Karina Raikhelson, Maria S. Gonzalez-Huezo, Michael A. Heneghan, Sook-Hyang Jeong, Alma L. Ladron de Guevara, Marlyn J. Mayo, George N. Dalekos, Joost P. H. Drenth, Ewa Janczewska, Barbara A. Leggett, Frederik Nevens, Victor Vargas, Eli Zuckerman, Christophe Corpechot, Eduardo Fassio, Holger Hinrichsen, Pietro Invernizzi, Palak J. Trivedi, Lisa Forman, David E. J. Jones, Stephen D. Ryder, Mark G. Swain, Alexandra Steinberg, Pol F. Boudes, Yun-Jung Choi, Charles A. McWherter
Summary: This study evaluated the efficacy and safety of seladelpar in patients with primary biliary cholangitis who had inadequate response or intolerance to ursodeoxycholic acid. The results showed that seladelpar significantly improved liver biochemistry and pruritus in these patients, and it was well tolerated.
Article
Gastroenterology & Hepatology
Grazia Pennisi, Marco Enea, Vincenzo Falco, Guruprasad P. Aithal, Naaventhan Palaniyappan, Yusuf Yilmaz, Jerome Boursier, Christophe Cassinotto, Victor de Ledinghen, Wah Kheong Chan, Sanjiv Mahadeva, Peter Eddowes, Philip Newsome, Thomas Karlas, Johannes Wiegand, Vincent Wai-Sun Wong, Joern M. Schattenberg, Christian Labenz, Won Kim, Myoung Seok Lee, Monica Lupsor-Platon, Jeremy F. L. Cobbold, Jian-Gao Fan, Feng Shen, Katharina Staufer, Michael Trauner, Rudolf Stauber, Atsushi Nakajima, Masato Yoneda, Elisabetta Bugianesi, Ramy Younes, Silvia Gaia, Ming-Hua Zheng, Calogero Camma, Quentin M. Anstee, Ferenc E. Mozes, Michael Pavlides, Salvatore Petta
Summary: This study evaluated the diagnostic accuracy of simple, noninvasive tests (NITs) in patients with non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes (T2D). The results showed that liver stiffness measurement (LSM) and AGILE 3+ were better at determining advanced fibrosis compared to serum tests. The evaluation of diagnostic methods for NAFLD with T2D is clinically significant.
Article
Gastroenterology & Hepatology
Mary E. Rinella, Jeffrey V. Lazarus, Vlad Ratziu, Sven M. Francque, Arun J. Sanyal, Fasiha Kanwal, Diana Romero, Manal F. Abdelmalek, Quentin M. Anstee, Juan Pablo Arab, Marco Arrese, Ramon Bataller, Ulrich Beuers, Jerome Boursier, Elisabetta Bugianesi, Christopher D. Byrne, Graciela E. Castro Narro, Abhijit Chowdhury, Helena Cortez-Pinto, Donna R. Cryer, Kenneth Cusi, Mohamed El-Kassas, Samuel Klein, Wayne Eskridge, Jiangao Fan, Samer Gawrieh, Cynthia D. Guy, Stephen A. Harrison, Seung Up Kim, Bart G. Koot, Marko Korenjak, Kris V. Kowdley, Florence Lacaille, Rohit Loomba, Robert Mitchell-Thain, Timothy R. Morgan, Elisabeth E. Powell, Michael Roden, Manuel Romero-Gomez, Marcelo Silva, Shivaram Prasad Singh, Silvia C. Sookoian, C. Wendy Spearman, Dina Tiniakos, Luca Valenti, Miriam B. Vos, Vincent Wai-Sun Wong, Stavra Xanthakos, Yusuf Yilmaz, Zobair Younossi, Ansley Hobbs, Marcela Villota-Rivas, Philip N. Newsome
Summary: This study aimed to determine if there was a need to change the nomenclature and definition of NAFLD and NASH. Through a Delphi process involving content experts and patient advocates, a consensus was reached to replace NAFLD with metabolic dysfunction-associated steatotic liver disease (MetALD) and modify the diagnostic criteria. The new nomenclature and criteria are widely supported, nonstigmatizing, and can improve awareness and patient identification.
Article
Multidisciplinary Sciences
Lorenz Balcar, David Bauer, Katharina Pomej, Tobias Meischl, Mattias Mandorfer, Thomas Reiberger, Michael Trauner, Bernhard Scheiner, Matthias Pinter
Summary: Immunotherapy is the new standard of care for hepatocellular carcinoma, but there is a need for biomarkers that predict treatment response and survival. This study suggests that the relative change in IgG after ICI treatment can serve as a negative prognostic marker in patients with HCC.
Article
Gastroenterology & Hepatology
Tomas Machacek, Claudia D. Fuchs, Franziska Winkelmann, Marcus Frank, Hubert Scharnagl, Tatjana Stojakovic, Martina Sombetzki, Michael Trauner
Summary: In this study, the researchers evaluated the effect of polyhydroxylated bile acids (BAs) on the inflammation and fibrosis caused by Schistosoma mansoni infection. They found that mice lacking the Bsep gene showed less hepatic inflammation and fibrosis after infection, which could be attributed to the changes in bile acid composition and blood pH resulting from the loss of Bsep gene, affecting parasite fecundity and thus attenuating the development of S. mansoni-induced hepatic inflammation and fibrosis.
LIVER INTERNATIONAL
(2023)
Article
Gastroenterology & Hepatology
Bernhard Scheiner, Katharina Lampichler, Katharina Pomej, Lucian Beer, Lorenz Balcar, Riccardo Sartoris, Mohamed Bouattour, Sabrina Sidali, Michael Trauner, Mattias Mandorfer, Thomas Reiberger, Martina Scharitzer, Dietmar Tamandl, David J. Pinato, Maxime Ronot, Matthias Pinter
Summary: This study evaluated the prognostic and predictive value of baseline transversal psoas muscle thickness (TPMT) measurement in patients with hepatocellular carcinoma (HCC) undergoing immunotherapy. The results showed that patients with sarcopenia had a poorer prognosis and a lower response to immunotherapy.
HEPATOLOGY COMMUNICATIONS
(2023)
Article
Gastroenterology & Hepatology
Claudia D. Fuchs, Thierry Claudel, Veronika Mlitz, Alessandra Riva, Moritz Menz, Ksenia Brusilovskaya, Felix Haller, Maximilian Baumgartner, Philipp Koenigshofer, Lukas W. Unger, Wilhelm Sjoeland, Hubert Scharnagl, Tatjana Stojakovic, Georg Busslinger, Thomas Reiberger, Hanns-Ulrich Marschall, Michael Trauner
Summary: The GLP-2 analogue teduglutide has hepatoprotective and antifibrotic effects in a mouse model of sclerosing cholangitis. GLP-2 treatment decreases hepatic inflammation and fibrosis, and activates the intestinal FXR-FGF15/19 signaling axis, resulting in reduced expression of Cyp7a1 and increased expression of Cyp2c70 in the liver, contributing to its protective effects.
CELLULAR AND MOLECULAR GASTROENTEROLOGY AND HEPATOLOGY
(2023)